Gastric Cancer Biomarker Array
CA19-9, CA72-4, CEA, Pepsinogen 1, Pepsinogen 2
Serum, Plasma, Cell Culture Supernatant, Cell Lysates, Tissue Lysates, Other Body Fluids
Multiplex Protein Detection
Dry the glass slide
Block array surface
Incubate with Samples and Standards
Incubate with Biotinylated Detection Antibody Cocktail
Incubate with Streptavidin-Conjugated Fluor
Disassemble the glass slide
Scan with a gene microarray laser scanner
Perform densitometry and analysis
Antibody Array Slide
Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Once thawed, please keep reagents under suitable conditions respectively. Do not use past expiration date.
Gastric cancer (GC) is the fourth most common malignant disease and the second leading cause of cancer-related death worldwide. Despite significant improvements in the survival of patients with GC over the past several decades, GC is often diagnosed at an advanced stage and prognoses is still unsatisfactory due to the high incidence of recurrence. Since GC is mostly asymptomatic until it progresses to advanced stages, the early detection using effective screening approaches is important to impair GC mortalities. Biomarkers are characteristics that are objectively measured and evaluated as an indicator of normal biologic process, pathogenic processes, or pharmacological response to a therapeutic intervention. Various biomarkers related to DNA, RNA, exosome, etc. have been found by recent advances in genome analysis. Development of these biomarkers in the field of cancer treatment is expected to greatly contribute to the progress of cancer, selection of appropriate therapeutic strategies and efficient follow-up programs.